Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Medpace posted accelerating Q2 revenue and bookings growth, expressing confidence in these trends continuing for the rest of the year.
— Haruki Toyama, Andy Romanowich, Rich Eisinger
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Medpace Holdings, Inc.
Medpace is a global clinical contract research organization featuring a robust balance sheet and strong cash generation. While near-term growth...
Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.
Medpace posted strong Q2 results that beat expectations on both top and bottom lines, leading to a full-year guidance upgrade. Furthermore, massive share...
More institutional theses from Madison Mid Cap Fund
Arthur J. Gallagher & Co. ($AJG) is the third-largest commercial insurance brokerage in the world, acting as an intermediary to help middle-market commercial clients evaluate, place, and administer insurance policies and risk management services. Madison initiated a...
Revvity ($RVTY) is a specialized life science tools and diagnostic testing company providing research informatics software, preclinical discovery reagents, and clinical diagnostic systems. Madison initiated a...
CDW Corporation ($CDW) operates as a large-scale value-added reseller and IT solutions provider, supplying business and government institutions with enterprise hardware, software, and cloud infrastructure integration. Madison fully liquidated...